# MDC Pharmacokinetics (PK) I Practice Exam (Sample)

## Study Guide

BY EXAMZIFY

**Everything you need from our exam experts!**

**Sample study guide. For the full version with hundreds of questions, visit: https://mdcpk1.examzify.com**

**Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.**

**ALL RIGHTS RESERVED.**

**No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.**

**Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.**

SAMPLE

# Table of Contents



SAMPLE

# Introduction

**Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.**

**This guide was designed to help you do exactly that.**

**Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.**

**The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:**

- **Practice answering questions under realistic conditions,**
- **Improve accuracy and speed,**
- **Review explanations to strengthen weak areas, and**
- **Approach the exam with greater confidence.**

**We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.**

**Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.**

**Let's begin.**

SAMPLE

# How to Use This Guide

**This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here’s how to get the most out of your Examzify study guide:**

### 1. Start with a Diagnostic Review

**Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.**

### 2. Study in Short, Focused Sessions

**Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.**

### 3. Learn from the Explanations

**After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.**

### 4. Track Your Progress

**Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.**

### 5. Simulate the Real Exam

**Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.**

### 6. Repeat and Review

**Don’t just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.**

**There’s no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!**

SAMPLE

# Questions

SAMPLE

**1. If intrinsic clearance is very high relative to hepatic blood flow, hepatic clearance approaches which factor?**

**A. Q**

**B. fu × CLint**

**C. Dose**

**D. F**

**2. An IV bolus delivers 300 mg into a system with Vd of 25 L. What is the initial concentration C0?**

**A. 12 mg/L**

**B. 25 mg/L**

**C. 15 mg/L**

**D. 300 mg/L**

**3. Which statement best defines volume of distribution and what a large Vd implies about tissue distribution?**

**A. Vd relates the amount of drug in the body to plasma concentration; large Vd implies extensive tissue distribution.**

**B. Vd is the physical volume of the body.**

**C. Vd measures the rate of distribution.**

**D. Vd equals clearance divided by rate constant.**

**4. What is the expression for AUC after a non-intravenous dose including bioavailability?**

**A. AUC = Dose / CL**

**B. AUC = F × Dose / CL**

**C. AUC = Dose × CL / F**

**D. AUC = Dose × F**

**5. How do you determine the maintenance dose for a target Css,avg with a known dosing interval?**

**A. MD = Css,avg × Cl × τ.**

**B. MD = Css,avg × Vd.**

**C. MD = Css,avg / (Cl × τ).**

**D. MD = Dose per interval.**

SAMPLE

**6. How can age or disease affect pharmacokinetic parameters such as clearance and volume of distribution?**

**A. Age or disease has no impact on clearance or Vd.**

**B. Age or disease only affects half-life but not clearance.**

**C. They randomly affect PK with no pattern.**

**D. They can alter organ function and body composition; aging may reduce clearance; obesity can increase Vd for lipophilic drugs; children often have different Vd and CL.**

**7. Which term refers to preparations that reduce excess fat in the body?**

**A. Decongestant**

**B. Anti-Obesity**

**C. Antipyretic**

**D. Anti-Gout**

**8. Which term means to prevent generation of gas in the intestine or stomach?**

**A. Antacid**

**B. Antiemetic**

**C. Antidiarrheal**

**D. Antiflatulent**

**9. What does 4–5 half-lives indicate in pharmacokinetics?**

**A. Time to reach approximately 50% of steady state.**

**B. Time to reach approximately 94–97% of steady state.**

**C. Time to eliminate 90% of drug.**

**D. Time to reach approximately 63% of steady state.**

**10. Which term is used for medicines that liquefy thick phlegm?**

**A. Antipyretic**

**B. Anti-Diabetic**

**C. Mucolytic**

**D. Decongestant**

SAMPLE

# Answers

SAMPLE

1. A
2. A
3. A
4. B
5. A
6. D
7. B
8. D
9. B
10. C

SAMPLE

# Explanations

SAMPLE

## 1. If intrinsic clearance is very high relative to hepatic blood flow, hepatic clearance approaches which factor?

**A. Q**

**B. fu × CLint**

**C. Dose**

**D. F**

**When the intrinsic clearance capacity of the liver is very high, the rate at which the liver can metabolize a drug is no longer the bottleneck—the delivery of drug to the liver becomes the limiting step. In the well-stirred model, hepatic clearance is given by CL_H = (Q × fu × CLint) / (Q + fu × CLint). If fu × CLint is much larger than Q, the expression simplifies to CL_H ≈ Q. So hepatic clearance approaches the hepatic blood flow rate, meaning the extraction is flow-limited (near 1). Dose or overall bioavailability don't set CL_H, and the large intrinsic clearance drives CL_H toward Q rather than away from it.**

## 2. An IV bolus delivers 300 mg into a system with Vd of 25 L. What is the initial concentration C0?

**A. 12 mg/L**

**B. 25 mg/L**

**C. 15 mg/L**

**D. 300 mg/L**

**For an IV bolus, the drug is instantly distributed within the volume of distribution, so the initial concentration equals the dose divided by Vd. C0 = Dose / Vd. Plugging in the values: C0 = 300 mg / 25 L = 12 mg/L. Thus the initial concentration is 12 mg/L. The other numbers would require a different Vd or dose, so they don't fit the given values.**

## 3. Which statement best defines volume of distribution and what a large Vd implies about tissue distribution?

**A. Vd relates the amount of drug in the body to plasma concentration; large Vd implies extensive tissue distribution.**

**B. Vd is the physical volume of the body.**

**C. Vd measures the rate of distribution.**

**D. Vd equals clearance divided by rate constant.**

**Volume of distribution tells you how a drug spreads between the blood and the tissues. It's defined as the amount of drug in the body divided by the plasma concentration. When this value is large, it means most of the drug is distributing into tissues rather than staying in the plasma, indicating extensive tissue distribution. This often happens with lipophilic drugs or those that bind strongly to tissue components, so a given dose yields a relatively low plasma concentration compared with the total amount in the body. Remember, Vd is a theoretical construct, not a physical organ or space, and a large Vd can even exceed the volume of body water, reflecting widespread tissue uptake. In practice, a large Vd also relates to longer elimination in many cases (t1/2 = 0.693 × Vd / Cl), since more drug resides in tissue away from plasma while clearance acts.**

SAMPLE

## 4. What is the expression for AUC after a non-intravenous dose including bioavailability?

**A. AUC = Dose / CL**

**B. AUC = F × Dose / CL**

**C. AUC = Dose × CL / F**

**D. AUC = Dose × F**

**Systemic exposure after a non-intravenous dose depends on how much drug actually reaches the circulation (bioavailability) and how quickly it is cleared. The AUC, which measures overall exposure, is proportional to the amount that gets into the bloodstream (F × Dose) and inversely proportional to clearance (CL). So the correct expression is AUC = (F × Dose) / CL. If the drug is given intravenously, F equals 1, reducing to AUC = Dose / CL. The other options miss the role of bioavailability (A), invert the relationship with clearance (C), or represent total administered dose rather than exposure (D).**

## 5. How do you determine the maintenance dose for a target Css,avg with a known dosing interval?

**A. MD = Css,avg × Cl × τ.**

**B. MD = Css,avg × Vd.**

**C. MD = Css,avg / (Cl × τ).**

**D. MD = Dose per interval.**

**To maintain a target average concentration (Css,avg) with a fixed dosing interval, you need a dose that replaces what is cleared during each interval. The amount eliminated at Css,avg is Css,avg × Cl, and over one dosing interval τ the total eliminated is Css,avg × Cl × τ. Therefore, the maintenance dose must equal that amount: MD = Css,avg × Cl × τ. This ensures the average level stays steady across intervals, with correct units (mg = mg/L × L/h × h). Using the volume of distribution would address distribution, not how fast the drug is cleared, so it doesn't set the maintenance dose. Dividing by Cl × τ would invert the correct relationship and give the wrong magnitude. Simply saying "dose per interval" lacks the necessary link to clearance and the dosing interval needed to achieve the target Css.**

SAMPLE

## 6. How can age or disease affect pharmacokinetic parameters such as clearance and volume of distribution?

**A. Age or disease has no impact on clearance or Vd.**

**B. Age or disease only affects half-life but not clearance.**

**C. They randomly affect PK with no pattern.**

**D. They can alter organ function and body composition; aging may reduce clearance; obesity can increase Vd for lipophilic drugs; children often have different Vd and CL.**

**Age and disease change how drugs move and are cleared because pharmacokinetics depends on the body's organ function and body composition. Clearance reflects how quickly a drug is removed, mainly by the liver and kidneys, and aging often reduces hepatic metabolism and renal function, lowering clearance. The volume of distribution depends on where the drug goes in the body; aging can shift body composition (less total body water, changes in fat) and obesity increases fat mass, which raises the Vd for lipophilic drugs. In children, maturation of organ systems means they often have different clearance rates and distribution volumes compared with adults. Disease states further modify these parameters: liver disease can reduce metabolism, kidney disease can reduce excretion, and conditions with edema, ascites, or low albumin can increase the apparent Vd or change protein binding. Obesity is a classic case where Vd for lipophilic drugs increases, while aging may reduce clearance. This combination of altered organ function and body composition is exactly what drives the changes in clearance and volume of distribution, making the described pattern the best answer.**

## 7. Which term refers to preparations that reduce excess fat in the body?

**A. Decongestant**

**B. Anti-Obesity**

**C. Antipyretic**

**D. Anti-Gout**

**The focus here is the label used for drugs that aim to decrease excess body fat. Anti-obesity preparations are the term that specifically denotes medications designed to reduce fat mass, typically by appetite suppression, increasing energy expenditure, or inhibiting fat absorption. The other terms describe different therapeutic goals and are not related to fat reduction: a decongestant relieves nasal congestion, an antipyretic lowers fever, and an anti-gout agent treats gout. None of these imply fat loss, so they wouldn't be used to describe preparations that reduce body fat. So, anti-obesity is the correct descriptor for preparations that reduce excess fat.**

SAMPLE

## 8. Which term means to prevent generation of gas in the intestine or stomach?

**A. Antacid**

**B. Antiemetic**

**C. Antidiarrheal**

**D. Antiflatulent**

**Antiflatulent is the term used for preventing gas buildup in the gut. These drugs don't stop gas production at the source; instead they act on the gas already present by lowering the surface tension of gas bubbles, causing them to coalesce and be expelled more easily. This helps relieve bloating, pressure, and discomfort from flatulence. A common example is simethicone. The other options target different GI issues—antacids neutralize stomach acid, antiemetics prevent nausea and vomiting, and antidiarrheals slow intestinal movement or reduce stool liquidity—so they don't address gas in the same way.**

## 9. What does 4–5 half-lives indicate in pharmacokinetics?

**A. Time to reach approximately 50% of steady state.**

**B. Time to reach approximately 94–97% of steady state.**

**C. Time to eliminate 90% of drug.**

**D. Time to reach approximately 63% of steady state.**

**The concept being tested is how long it takes for drug levels to reach steady state with repeated dosing, and how that buildup is governed by the elimination half-life. With each half-life, the remaining distance to steady state is halved, so after n half-lives you're about 1 − (1/2)^n of the way there. Numerically, four half-lives bring you to about 93.75% of steady state, and five half-lives to about 96.9%. That's why four to five half-lives indicate a near-complete attainment of steady-state concentrations, roughly 94–97% of steady state. For context, reaching 50% of steady state happens after one half-life, and reaching about 63% corresponds to about 0.69 half-lives, not four or five. Eliminating 90% of the drug from the body would occur after roughly 3.3 half-lives, which is another rule of thumb but not the one about approaching steady state with dosing.**

## 10. Which term is used for medicines that liquefy thick phlegm?

**A. Antipyretic**

**B. Anti-Diabetic**

**C. Mucolytic**

**D. Decongestant**

**Mucolytics are medicines that liquefy thick phlegm. In the airways, mucus is a gel formed by mucin proteins linked by disulfide bonds. Mucolytic drugs break those bonds or otherwise disrupt the mucus structure, lowering its viscosity so it can be coughed up more easily. This thinning of mucus helps clear the airways in conditions with sticky, thick sputum. Classic examples include N-acetylcysteine (which also serves as an antioxidant precursor) and carbocisteine. That's why this term best fits the description. Antipyretics reduce fever, anti-diabetics control blood glucose, and decongestants mainly ease nasal congestion through vasoconstriction but don't liquefy thick phlegm.**

SAMPLE

# Next Steps

**Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.**

**As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.**

**If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.**

**Or visit your dedicated course page for more study tools and resources:**

**https://mdcpk1.examzify.com**

**We wish you the very best on your exam journey. You've got this!**

SAMPLE